메뉴 건너뛰기
Current Medical Research and Opinion
Volumn 27, Issue 1, 2011, Pages 79-86
Comparative effectiveness of colony-stimulating factors for febrile neutropenia: A retrospective study
Author keywords

Colony stimulating factors; Comparative effectiveness; Febrile neutropenia; Filgrastim; G CSF; Pegfilgrastim
Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
EID: 78650348222     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.536527     Document Type: Article
Times cited : (53)
References (17)
  • 1
    • 0005224217 scopus 로고    scopus 로고
    • Draft Definition, Prioritization Criteria, and Strategic Framework for Public Comment Available at [Last accessed 24 August 2009]
    • Draft Definition, Prioritization Criteria, and Strategic Framework for Public Comment. Department of Health and Human Services, 2009. Available at http://www.hhs.gov/recovery/programs/cer/draftdefinition.html [Last accessed 24 August 2009]
    • (2009) Department of Health and Human Services
  • 2
    • 34547670214 scopus 로고    scopus 로고
    • Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
    • Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
    • (2007) J Clin Oncol , vol.25 , pp. 3158-67
    • Kuderer, N.M.1    Dale, D.C.2    Crawford, J.3
  • 3
    • 33646379875 scopus 로고    scopus 로고
    • Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
    • Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106:2258-66
    • (2006) Cancer , vol.106 , pp. 2258-66
    • Kuderer, N.M.1    Dale, D.C.2    Crawford, J.3
  • 4
    • 68049109174 scopus 로고    scopus 로고
    • package insert Thousand Oaks CA, Amgen Inc
    • Neupogen [package insert]. 2007. Thousand Oaks, CA, Amgen Inc
    • (2007) Neupogen
  • 5
    • 78650324375 scopus 로고    scopus 로고
    • package insert Thousand Oaks CA, Amgen Inc
    • Neulasta [package insert]. 2008. Thousand Oaks, CA, Amgen Inc
    • (2008) Neulasta
  • 6
    • 0035990090 scopus 로고    scopus 로고
    • Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer
    • Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9
    • (2002) Ann Oncol , vol.13 , pp. 903-9
    • Holmes, F.A.1    Jones, S.E.2    O'Shaughnessy, J.3
  • 7
    • 0037250159 scopus 로고    scopus 로고
    • A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
    • Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
    • (2003) Ann Oncol , vol.14 , pp. 29-35
    • Green, M.D.1    Koelbl, H.2    Baselga, J.3
  • 8
    • 34250717295 scopus 로고    scopus 로고
    • Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfil-grastim associated with 3-4 week chemotherapy regimens in community oncology practices
    • Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfil-grastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337-48
    • (2007) J Manag Care Pharm , vol.13 , pp. 337-48
    • Morrison, V.A.1    Wong, M.2    Hershman, D.3
  • 9
    • 33645048438 scopus 로고    scopus 로고
    • Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
    • Weycker D, Hackett J, Edelsberg JS, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402-7
    • (2006) Ann Pharmacother , vol.40 , pp. 402-7
    • Weycker, D.1    Hackett, J.2    Edelsberg, J.S.3
  • 10
    • 66949174442 scopus 로고    scopus 로고
    • Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study
    • Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009;31:1069-81
    • (2009) Clin Ther , vol.31 , pp. 1069-81
    • Weycker, D.1    Malin, J.2    Kim, J.3
  • 11
    • 33646368373 scopus 로고    scopus 로고
    • Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States)
    • Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 2006; 17:647-54
    • (2006) Cancer Causes Control , vol.17 , pp. 647-54
    • Chen-Hardee, S.1    Chrischilles, E.A.2    Voelker, M.D.3
  • 12
    • 0022673130 scopus 로고
    • Longitudinal data analysis for discrete and continuous outcomes
    • Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30
    • (1986) Biometrics , vol.42 , pp. 121-30
    • Zeger, S.L.1    Liang, K.Y.2
  • 13
    • 0030862072 scopus 로고    scopus 로고
    • Estimating causal effects from large data sets using propensity scores
    • Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63
    • (1997) Ann Intern Med , vol.127 , pp. 757-63
    • Rubin, D.B.1
  • 14
    • 78650363530 scopus 로고    scopus 로고
    • Stata Statistical Software College Station TX: StataCorp LP. StataCorp
    • Stata Statistical Software: Release 10. College Station, TX: StataCorp LP. StataCorp, 2007
    • (2007) Release 10
  • 15
    • 1542358091 scopus 로고    scopus 로고
    • Screening for hepatitis C virus infection: A review of the evidence for the U.S. Preventive Services Task Force
    • Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:465-79
    • (2004) Ann Intern Med , vol.140 , pp. 465-79
    • Chou, R.1    Clark, E.C.2    Helfand, M.3
  • 16
    • 0037133079 scopus 로고    scopus 로고
    • Surprisingly small effect of antiviral treatment in patients with hepatitis C
    • Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92
    • (2002) Ann Intern Med , vol.136 , pp. 288-92
    • Falck-Ytter, Y.1    Kale, H.2    Mullen, K.D.3
  • 17
    • 68149123409 scopus 로고    scopus 로고
    • Impact of asthma controller medications on clinical, economic, and patient-reported outcomes
    • Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009; 84:675-84
    • (2009) Mayo Clin Proc , vol.84 , pp. 675-84
    • Tan, H.1    Sarawate, C.2    Singer, J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.